"GIP's Role in Obesity Research: A Controversial Debate"

A landmark study over a decade ago suggested a new approach to treating obesity and diabetes by activating gut hormone receptors GLP-1 and GIP. This approach was used by Eli Lilly to develop tirzepatide, a medicine for diabetes and weight loss. However, recent research has raised questions about the effectiveness of GIP in treating obesity, leading to conflicting views within the scientific community.